Companies: 10,795·Total market cap: $144.5T
Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGRQOTCHealthcare
$8.50
+$0.50(+6.25%)
Market Cap$12586800
P/E Ratio
52W High$16.0
52W Low$1.1

Eiger BioPharmaceuticals, Inc. (EIGRQ) Revenue

Annual & quarterly revenue history · segment & region breakdown

EIGRQ · revenue · updated Jun 10, 2026

Core revenue metrics

Eiger BioPharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 0.00% year-over-year from — in FY.

TTM revenue
$0.02B
4-quarter sum · USD
YoY growth
+0.00%
vs FY
Price / sales
0.80×
mktCap ÷ TTM rev
Revenue per day
$0M
Est. TTM ÷ 365
Revenue / employee
$631K
25 employees
FY
FY
5Y CAGR
Fiscal year end
Dec 31
Currency
USD · GAAP
Filing
10-K / 10-Q
Source: FMP · Eiger BioPharmaceuticals, Inc. SEC filings · GAAPUpdated: 2026-06-10

Revenue trend

· Annual
YoY revenue growth %
revenue trend · revenue chart · revenue by year · revenue history

Revenue history

Fiscal year endRevenueChangeGrowth
EIGRQ revenue by year · EIGRQ revenue history · EIGRQ annual revenue data

About Revenue & Reporting

Revenue (also called sales, net sales, or turnover) is the total income Eiger BioPharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.

Eiger BioPharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.

Data sourced from Eiger BioPharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.

Figures tie to SEC 10-K/10-Q and FMP income-statement endpoints where noted.

Frequently asked questions

EIGRQ revenue · 4 questions

EIGRQ's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 0.00% year-over-year from — in FY.

EIGRQ revenueEIGRQ annual revenuewhat is EIGRQ revenueEIGRQ TTM revenue

Source: FMP · Eiger BioPharmaceuticals, Inc. SEC filings · GAAP · Eiger BioPharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026